Efficacy and Safety of TRK-700 in Patient With Post-Herpetic Neuralgia

• Status: Completed
• Trial end date: 2017-07-01
• Target enrollment: 0
• Participant gender: All

Summary

In Post-Herpetic Neuralgia(PHN) patients:

• To conduct an explorative investigation of the efficacy and safety of repeated oral doses of TRK-700 via a randomized double blind comparative study

• To measure the plasma concentration of TRK-700 and its metabolites

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Toray Industries, Inc

Criteria

Inclusion Criteria:

• Patients with pain persisting for at least 3 months after the onset of herpes zoster

• Patients whose average pain score on the Numerical Rating Scale (NRS) over the past 24 hours at preliminary enrollment is at least 4

Exclusion Criteria:

• Patients with another skin disease that may affect the evaluation of the pain at the site of PHN

• Patients with pain other than PHN that may affect the evaluation of pain

• Patients with pain that is suspected to be mainly psychogenic

• Patients who have received neurolytic or neurosurgical therapy for PHN